Explore Astrazeneca's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 24, 2025
Patent NumberGrant DateTitleTotal Oppositions
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery2
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
Apr 3, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
Sep 13, 2023Sustained Release Formulations Using Non-Aqueous Carriers1
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
Apr 19, 2023Stable Anti-Ifnar1 Formulation1
Nov 9, 2022Combination Treatment Of Cancer1
Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor1